Get alerts
Open

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Federal funding opportunity PAR-28-072 from National Institutes of Health (Department of Health and Human Services).

Apply on Grants.gov →Application closes November 16, 2029

Posted
September 25, 2026
Closes
November 16, 2029
Cost sharing
No
Instrument
Grant
Assistance listing
93.867
Category
Health
Archives
January 15, 2030

Program funding history

Awards made under Assistance Listing 93.867 across FY2025–FY2027, from public federal spending records.

FY2025 obligated
$696.7M
FY2026 obligated
$693.8M
FY2027 (to date) obligated
$0
Awards in window
3,058

Top recipients: The Johns Hopkins University, The Leland Stanford Junior University, Jaeb Center for Health Research Foundation, Inc., Regents of the University of California, San Francisco, the, University of California, Los Angeles

Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →

Synopsis

The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system. The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to four years and will support research that is in the final states of preclinical development with potential for near-term clinical development. The total duration of both R61 and R33 cannot exceed five years. The R33 is to focus on advancing a single therapeutic candidate through Investigational New Drug or Investigational Device Exemption (IND/IDE) enabling studies, filing an IND/IDE package with the FDA, and designing future clinical trials. R33 recipients must submit or obtain an IND/IDE application to FDA, or must transition the product to clinical practice, within the period of performance. The specific activities appropriate for the R33 phase will depend on the product under study and available preliminary data on the product. Delineation of milestones by the applicant for the R61 and R33 phases is a key characteristic of this program. A milestone is defined as a scheduled event in the project timeline that signifies the completion of a major project stage or activity. This program will support applications that propose a series of milestones including manufacturing and product development goals. Applications that address contingency plans to proactively confront potential delays in meeting the milestones are strongly encouraged. Milestones are required for both phases. Milestones must be specific, measurable, achievable, relevant, and time-bound (SMART). All projects will begin with a R61 phase regardless of therapeutic starting point.

Who can apply

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards. Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.

View on Grants.gov

Agency contact: National Institutes of Health · [email protected] · 301-402-2541

New to federal funding? How to read an announcement · Who can apply · How grants work

Remind me before this closes

One email about a week before this grant closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.

Stored once per grant, used only for this watch’s emails; every one carries a one-click unsubscribe. Privacy

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.

No spam, ever. Privacy

Similar grants

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.

Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.

See pricing